Manousopoulou A, et al. - In this trial, researchers studied in patients with non-alcoholic fatty liver disease (NAFLD) the system-wide effects of treatment with docosahexaenoic acid + eicosapentaenoic acid (DHA+EPA) compared with placebo on the plasma proteome. Using depletion-free quantitative proteomics, plasma from patients that partook in 15 to 18 months randomised, double-blind placebo-controlled trial testing the effects of 4 g DHA+EPA daily was investigated. Plasma proteomics applied in a randomised, placebo-controlled trial demonstrated that high dose DHA+EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-communicable diseases. As a result of DHA+EPA supplementation, prothrombin and apolipoprotein B-100 were shown to decrease.